Avenue Therapeutics Stock Forecast, Price & News

Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

How has Avenue Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Avenue Therapeutics' stock was trading at $7.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATXI stock has decreased by 90.7% and is now trading at $0.69.
View which stocks have been most impacted by COVID-19.

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 505,600 shares, a decrease of 23.7% from the December 15th total of 662,500 shares. Based on an average daily trading volume, of 493,400 shares, the days-to-cover ratio is presently 1.0 days. Approximately 6.2% of the company's stock are short sold.
View Avenue Therapeutics' Short Interest.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) issued its quarterly earnings data on Sunday, November, 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.05).
View Avenue Therapeutics' earnings history.

Who are Avenue Therapeutics' key executives?

Avenue Therapeutics' management team includes the following people:

• Lucy Lu, President, Chief Executive Officer & Director
• Joseph Vazzano, Chief Financial Officer & Secretary
• Scott A. Reines, Chief Medical Officer

Who are some of Avenue Therapeutics' key competitors?

Some companies that are related to Avenue Therapeutics include Synaptogenix (SNPX), Gain Therapeutics (GANX), Cocrystal Pharma (COCP), Statera BioPharma (STAB), NeuBase Therapeutics (NBSE), Cumberland Pharmaceuticals (CPIX), Marker Therapeutics (MRKR), DiaMedica Therapeutics (DMAC), Aprea Therapeutics (APRE), IntelGenx Technologies (IGXT), Adial Pharmaceuticals (ADIL), Aravive (ARAV), Addex Therapeutics (ADXN), IMARA (IMRA) and Stealth BioTherapeutics (MITO).
View all of ATXI's competitors.

What other stocks do shareholders of Avenue Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO).

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $0.69.

How much money does Avenue Therapeutics make?

Avenue Therapeutics has a market capitalization of $13.10 million.

How many employees does Avenue Therapeutics have?

Avenue Therapeutics employs 4 workers across the globe.

What is Avenue Therapeutics' official website?

The official website for Avenue Therapeutics is www.avenuetx.com.

Where are Avenue Therapeutics' headquarters?

Avenue Therapeutics is headquartered at 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The company can be reached via phone at (781) 652-4500 or via email at [email protected].